Changes

==Primary Author(s)*==

==Primary Author(s)*==

Dr Kay Weng Choy MBBS, BMedSci, FAACB, Monash Health

Kay Weng Choy, MBBS, Monash Medical Centre

__TOC__

__TOC__

==Cancer Category/Type==

==Cancer Category/Type==

[[Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms]]

[[HAEM4:Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms]]

[[Acute Myeloid Leukemia (AML) with Mutated FLT3]]

 

[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement]]

''FLT3'' mutations occur in about one-third of patients with AML [3]. In-frame duplications of 3 to >400 base pairs, also known as internal tandem duplications (ITDs), are the most common mutations in ''FLT3'' and they occur in up to 30% of adult patients with ''de novo'' AML [3,4,5,6]. About 70% of ''FLT3''-ITDs occur in the JMD and about 30% in the TKD [3]. The JMD inhibits activation of the receptor by steric hindrance, preventing the TKD from assuming an active conformation; presence of an ITD causes loss of this inhibitory effect, resulting in activation of the TKD.

''FLT3'' mutations occur in about one-third of patients with AML [3]. In-frame duplications of 3 to >400 base pairs, also known as internal tandem duplications (ITDs), are the most common mutations in ''FLT3'' and they occur in up to 30% of adult patients with ''de novo'' AML [3,4,5,6]. About 70% of ''FLT3''-ITDs occur in the JMD and about 30% in the TKD [3]. The JMD inhibits activation of the receptor by steric hindrance, preventing the TKD from assuming an active conformation; presence of an ITD causes loss of this inhibitory effect, resulting in activation of the TKD.

{| class="wikitable sortable"

{| class="wikitable sortable"

|-

|-

! Copy Number Loss   !! Copy Number Gain   !! LOH   !!   Loss-of-Function Mutation   !! Gain-of-Function Mutation !! Translocation/Fusion  

!Copy Number Loss!!Copy Number Gain!!LOH!!Loss-of-Function Mutation!!Gain-of-Function Mutation!!Translocation/Fusion

|-

|-

| || ||   || || X ||  

| || || || ||X||

|}

|}

==Internal Pages==

==Internal Pages==

[[Acute Myeloid Leukemia (AML) with Mutated FLT3]]

[[HAEM5:Myeloid/lymphoid neoplasm with FLT3 rearrangement]]

==External Links==

==External Links==

7. Smith CC, et al., (2012). Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485:260-263. PMID 22504184.

7. Smith CC, et al., (2012). Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 485:260-263. PMID 22504184.

== Notes ==

==Notes==

<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.

<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.